ELOA2 (elongin A2) is a transcription elongation factor that enhances RNA polymerase II transcription elongation by suppressing transient polymerase pausing at template-encoded arrest sites 1. As a member of the Elongin protein family, ELOA2 shares 47% identity with Elongin A and stimulates the rate of transcription elongation, with nuclear localization and capability to form stable complexes with the Elongin BC regulatory subunits 1. Unlike Elongin A, ELOA2's transcriptional activity is not enhanced by binding to the Elongin BC complex, distinguishing it functionally within the Elongin family 12. ELOA2 mRNA is specifically expressed in testis tissue, suggesting a role in testis-specific gene regulation 1. In disease relevance, ELOA2 was identified as one of six prognosis-related genes in a predictive model for endometrial cancer, where it was highly expressed in endometrial cancer tissues compared to normal tissues 3. These findings suggest ELOA2 may serve as a potential biomarker for endometrial cancer risk stratification and prognosis prediction, though its mechanistic role in cancer pathogenesis requires further investigation.